Navigation Links
Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
Date:2/11/2013

CASTLE ROCK, Colo., Feb. 11, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that its presentation at the 2013 BIO CEO and Investor Conference, to be held February 11-12, 2013, at the Waldorf Astoria Hotel in New York, has been rescheduled for Tuesday, February 12, 2013. 

Steve Lundy , President and CEO of Venaxis, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Event:BIO CEO and Investor ConferenceDate: Tuesday, February 12, 2013 Time: 10:00 am (Eastern Time) Location:Astor Room, 3rd Floor; Waldorf Astoria Hotel; New YorkThe presentation will be webcast live.  To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com.  The webcast replay will remain available for 90 days.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1.  The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") (formerly AspenBio Pharma, Inc.) as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from APPY1, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:
Joshua Drumm , PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
jrando@tiberend.com


'/>"/>
SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Venaxis to Present at 2013 BIO CEO and Investor Conference
2. AspenBio Pharma Changes Company Name to Venaxis, Inc.
3. Thoratec Presentation at Leerink Swann Global Healthcare Conference to Be Webcast
4. Vasomedical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
8. Wacoms DTH-2242: An Ideal Interactive Pen and Touch Display Solution for Healthcare and Presentation Markets
9. Présentation du tout premier test pratique dévaluation des compétences pour la certification dendoscopie
10. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
11. Thoratec Presentation At Oppenheimer 23rd Annual Healthcare Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 Dutch surgeons have ... practices around the world and treat patients on a global scale. ... , Asia and the US have ... instant messaging and networking in a totally secure environment. ... a war zone working together with a surgeon at Harvard to ...
(Date:5/23/2016)... --Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the start ... hands-on learning experience is a 12-week summer program, May ... and Internship programs bring participants to ... are provided optional housing free of charge through Diplomat ... Riverfront Residence Hall to foster communication and collaboration among ...
(Date:5/23/2016)... May 23, 2016 The World Health Organization (WHO) ... device to include adolescents aged 13 years, and above. Effective ... offered for adult and adolescent males in the 14 priority ... PrePex was the first male circumcision device to receive WHO ... Eddy Horowitz said: " The expanded ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... ... Georgia State University College of Law new building at 85 Park Place has received ... recognizes projects, programs, individuals and organizations that have significantly contributed toward the enhancement of ... balance between the old and the new. , “Winning a 2016 Award of Excellence ...
(Date:5/25/2016)... ... 25, 2016 , ... Serenity Recovery, a holistic treatment center ... of the many supplemental program options offered at their rehabilitation facility, this time ... Black Belt in the Shorin-ryu style of Karate that originated in Okinawa, Japan, ...
(Date:5/25/2016)... ... ... an article published May 5th on The Daily Mail, a survey pointed out ... found that more than a third cited unappealing breath a one of their top dating ... failure to brush after meals, can typically be attributed to gum disease. Moreover, the article ...
(Date:5/25/2016)... ... May 25, 2016 , ... One Florida-based plastic surgeon’s enthusiasm ... to an article published May 13th on Vanity Fair. In fact, as ... snippets of their procedures broadcast to more than 800,000 Snapchat fans. Commenting on this ...
(Date:5/25/2016)... ... ... There was a time when tampons and pads were the only options for women for ... cups, like Lunette . To make that time of the month less of a ... video ! , It’s easy to see why Lunette is so popular. Lunette ...
Breaking Medicine News(10 mins):